Amicus Therapeutics (FOLD) Hit Pre-Market
Tweet
Share
E-mailGet Alerts FOLD Hot Sheet
Join SI Premium – FREE
Shares of Amicus Therapeutics (Nasdaq: FOLD) declined pre-market on Monday. The company hosted a conference call at 8:00 a.m. ET this morning. CEO John Crowley discussed the regulatory strategy for migalastat HCl monotherapy for Fabry disease following a recent Type C meeting with the U.S. Food and Drug Administration (FDA).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Exclusive: PayPal cuts 220 jobs in India, 160 in Ireland
- Grok, OpenAI, Claude all down simultaneously - Downdetector
- Trump: US Producing Munitions At Levels Never Seen Before
Create E-mail Alert Related Categories
Management Comments, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
